

Medicare Part B Preferred drug list — Aetna Better Health® Premier Plan (Medicare-Medicaid Plan).

Some medically administered Part B drugs may have extra requirements or limits on coverage. These may include step therapy. This is when we require you to first try certain preferred drugs to treat your medical condition before covering another non-preferred drug.

For example, if drug A and drug B both treat your condition, we may prefer drug A, and require you to try it first. If drug A does not work for you, we will then cover drug B. The listed preferred products should be used first. An exception process is in place for specific cases that may call for a non-preferred product.

Drug classes with preferred products are listed below. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna® website.

To find out more, go to AetnaBetterHealth.com/Michigan.

You can also call us at the number on your ID card.

Drug Class/Indication(s)	Non-Preferred Product(s)	Preferred Product(s)
Alpha-1 proteinase inhibitors	Aralast NP Glassia Zemaira	Prolastin-C
Bone Resorption Inhibitors • Hypercalcemia of malignancy	Xgeva	Pamidronate Zoledronic acid
 Botulinum Toxins Blepharospasm Cervical dystonia Chronic sialorrhea Upper limb spasticity 	Daxxify Dysport Myobloc	Botox Xeomin
Botulinum ToxinsAll other indications		Botox
 Complement Inhibitors Hemolytic uremic syndrome Myasthenia gravis Paroxysmal nocturnal hemoglobinuria 		Soliris Ultomiris
Complement Inhibitors • Neuromyelitis optica spectrum disorder		Soliris



		March 2024
CSF — Leukocyte Growth Factors (filgrastim)	Granix Leukine Neupogen Nivestym Releuko	Zarxio
CSF — Leukocyte Growth Factors (pegfilgrastim)	Fylnetra Nyvepria Rolvedon Stimufend Udenyca Udenyca Onbody (effective 4/1/24)	Fulphila Neulasta Neulasta Onpro
 Erythropoiesis Stimulating Agents Anemia due to chronic kidney disease Anemia due to chemotherapy Erythropoiesis Stimulating Agents 	Epogen Retacrit Jesduvroq	Aranesp Procrit
 Anemia due to Zidovudine use in HIV Transfusion reduction for select surgeries 		
Enzyme replacement therapy	Vpriv	Cerezyme Elelyso
Factor VIII (recombinant) • Hemophilia A (prophylaxis)	Advate Afstyla Nuwiq NovoEight Xyntha	Kovaltry
Gonadotropin-Releasing Hormone Agonists • Advanced prostate cancer	Lupron depot Trelstar Zoladex	Eligard
Gonadotropin-Releasing Hormone Antagonists		Firmagon
Immunologics (B through B) • Ulcerative colitis	Avsola Renflexis	Inflectra Entyvio Remicade Unbranded infliximab
Immunologics (B through B) • Crohn's disease		Entyvio
Intravenous iron	Feraheme Injectafer	Ferrlecit Sodium ferric gluconate





		IVIAICII 2024
 Iron deficiency anemia after intolerance or unsatisfactory response to oral iron 	Monoferric	Infed Venofer
IVIG (intravenous immunoglobulin)	Asceniv Bivigam Flebogamma Gammagard Liquid Gammagard S/D Gammaplex Panzyga	Gammaked Gamunex-C Octagam Privigen
SCIG (subcutaneous immunoglobulin)	Cutaquig Cuvitru Gammagard Liquid HyQvia	Gammaked Gamunex-C Hizentra Xembify
Multiple sclerosis		Tysabri
Oncology • Breast cancer	Perjeta	Phesgo
Oncology (Abraxane)	Abraxane Paclitaxel (protein bound)	Docetaxel Paclitaxel
Oncology (Avastin)	Alymsys Avastin Vegzelma	Mvasi Zirabev
Oncology (Herceptin)	Herceptin Herceptin Hylecta Herzuma Ogivri Ontruzant	Kanjinti Trazimera
Oncology (Multiple myeloma)	Darzalex Darzalex Faspro Empliciti Kyprolis Sarclisa	Bortezomib
Oncology (PD1/PDL1) • Squamous cell carcinoma	Keytruda	Libtayo





		March 2024
Oncology (PD1/PDL1) • Non-small cell lung cancer	Imfinzi Keytruda Opdivo Tecentriq	Libtayo
Oncology (Pemetrexed)	Pemfexy	Alimta Pemetrexed
Oncology (Rituximab) • All requests except rheumatoid arthritis	Riabni Rituxan Rituxan Hycela	Ruxience Truxima
Osteoarthritis	Zilretta	Kenalog Depo-medrol Triamcinolone acetonide Methylprednisolone acetate
Severe asthma	Cinqair Nucala Xolair	Fasenra
Somatostatin analogues	Lanreotide (Cipla) Signifor LAR	Sandostatin LAR Somatuline depot
VEGF inhibitors (ophthalmic)	Beovu Eylea (through 3/31/24) Eylea HD (through 3/31/24) Cimerli Lucentis Susvimo Vabysmo	Bevacizumab (Avastin) Byooviz after trial/failure of bevacizumab (Avastin) (Eylea/Eylea HD will also be preferred after trial/failure of bevacizumab effective 4/1/24)
Viscosupplements (single injection)	Gel-One Monovisc	Durolane Synvisc-One
Viscosupplements (multiple injections)	Gelsyn-3 GenVisc Hyalgan Hymovis Orthovisc Supartz FX TriVisc Visco-3	Euflexxa Synvisc




For the following classes, preferred products may be covered under the Part D (pharmacy) benefit:

Drug Class	Non-preferred Product(s)	Preferred Product(s)*
Bone Resorption Inhibitors • Osteoporosis	Evenity	Teriparatide
Immunologics • Crohn's disease	Actemra Avsola Cimzia Ilumya	Humira Rinvoq Skyrizi Stelara
Immunologics • Ankylosing spondylitis	Inflectra Orencia Remicade Renflexis	Enbrel Humira Xeljanz/Xeljanz XR Rinvoq
Immunologics • Juvenile idiopathic arthritis	Riabni Rituxan Ruxience	Enbrel Humira Xeljanz
Immunologics • Plaque psoriasis	Simponi Aria Truxima Tyruko Tysabri Unbranded infliximab	Enbrel Humira Otezla Skyrizi Stelara
Immunologics • Psoriatic arthritis		Enbrel Humira Otezla Rinvoq Skyrizi Stelara Xeljanz/Xeljanz XR
Immunologics • Rheumatoid arthritis		Enbrel Humira Kevzara Rinvoq Xeljanz/Xeljanz XR
 Multiple Sclerosis (relapsing forms) Clinically isolated syndrome Relapsing-remitting disease Active secondary progressive disease 	Briumvi Lemtrada Ocrevus	Kesimpta







PCSK9 inhibitors	Leqvio	Repatha
Systemic lupus erythematosus	Saphnelo	IV Benlysta (Part B) SC Benylsta (Part D)

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. For specific medical indications subject to step therapy, please see the corresponding clinical policy bulletin on the Aetna website.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Aetna. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

See Member Handbook for a complete description of plan benefits, exclusions, limitations, and conditions of coverage. Plan features and availability may vary by service area. The formulary and/or pharmacy network may change at any time. You will receive notice when necessary.

Aetna Better Health Premier Plan is a health plan that contracts with both Medicare and Michigan Medicaid to provide benefits of both programs to enrollees.

©2023 Aetna Inc.